Laurion Capital Management LP Lineage Cell Therapeutics, Inc. Transaction History

Laurion Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.91 - $1.35 $1.39 Million - $2.07 Million	-1,532,499 Reduced 77.94%	433,748 $472,000
Q2 2023 Aug 14, 2023	SELL	$1.26 - $1.53 $518,733 - $629,890	-411,693 Reduced 17.31%	1,966,247 $2.77 Million
Q3 2022 Nov 14, 2022	SELL	$1.13 - $1.77 $50,202 - $78,635	-44,427 Reduced 1.83%	2,377,940 $2.69 Million
Q2 2022 Aug 15, 2022	BUY	$1.12 - $1.61 $2.71 Million - $3.9 Million	2,422,367 New	2,422,367 $3.83 Million
Q3 2020 Nov 13, 2020	SELL	$0.75 - $1.09 $9,357 - $13,598	-12,476 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$0.71 - $1.18 $8,857 - $14,721	12,476 New	12,476 $11,000

120

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $91.7M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.